SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cohance Lifesciences - Quaterly Results

13 Nov 2025 Evaluate
The sales for the September 2025 quarter moved down to Rs. 4977.90 millions as compared to Rs. 5944.30 millions during the year-ago period.Profit after Tax for the quarter ended September 2025 saw a decline of -32.21% from Rs. 1391.00 millions to Rs. 942.90  millions.Operating Profit reported a sharp decline to 1571.60 millions from 2192.80 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 4977.90 5944.30 -16.26 9813.70 10825.10 -9.34 10935.10 10513.50 4.01
Other Income 263.00 157.60 66.88 394.00 351.70 12.03 539.80 566.10 -4.65
PBIDT 1571.60 2192.80 -28.33 2744.60 3638.60 -24.57 4165.50 4624.70 -9.93
Interest 52.40 94.20 -44.37 120.40 196.20 -38.63 80.00 74.50 7.38
PBDT 1519.20 2098.60 -27.61 2543.20 3442.40 -26.12 4085.50 4550.20 -10.21
Depreciation 312.00 345.60 -9.72 625.60 658.40 -4.98 572.00 546.00 4.76
PBT 1207.20 1753.00 -31.14 1917.60 2784.00 -31.12 3513.50 4004.20 -12.25
TAX 264.30 362.00 -26.99 449.00 638.50 -29.68 796.40 1039.50 -23.39
Deferred Tax 2.20 -77.10 -102.85 5.40 -68.20 -107.92 -127.30 65.90 -293.17
PAT 942.90 1391.00 -32.21 1468.60 2145.50 -31.55 2717.10 2964.70 -8.35
Equity 382.60 254.60 50.27 382.60 254.60 50.27 254.60 254.60 0.00
PBIDTM(%) 31.57 36.89 -14.42 27.97 33.61 -16.80 38.09 43.99 -13.40

Cohance Lifesciences Share Price

361.90 -7.45 (-2.02%)
21-Apr-2026 11:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1667.50
Dr. Reddys Lab 1221.70
Cipla 1231.85
Zydus Lifesciences 929.50
Lupin 2322.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×